Banner image placeholder
Banner image

Who we are


We are enthusiastic about cancer research. Our goal is to contribute to better outcomes for cancer patients by focussing our research efforts in two main areas. We develop novel immunotherapeutic approaches in hematological cancers and solid tumors and we use liquid biopsies to understand the cancer genome and  measure treatment response in cancer patients at high resolution.

Publications


Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy


Conrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, Michael Winkelmann, Andrea Farolfi, Laura Beckmann, Beatrice Casadei, Ken Herrmann, Nadine Kutsch, Peter Borchmann, Matthias Brendel, Viktoria Blumenberg, Stefano Fanti, Pier Luigi Zinzani, Kambiz Rahbar, Gabriel T Sheikh, Osama Sabri, Alexander Drzezga, Markus Dietlein, H Christian Reinhardt, Wolfgang G Kunz, Jörn C Albring, Robert Seifert, Bastian von Tresckow, Jan-Michel Heger, Philipp Gödel, Marion Subklewe, Andrea Paccagnella, Vladan Vučinić, Christine Hanoun

J Nucl Med, 2026


MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay


Jan-Michel Heger, Julia Mattlener, Helen Kaul, Justin Ferdinandus, Jessica Schneider, Julia K Schleifenbaum, Gundolf Schneider, Valdete Schaub, Mathias Hänel, Johannes C Hellmuth, Judith Dierlamm, Sonja Martin, Stephan Mathas, Julia Meissner, D Michiel Pegtel, Josée M Zijlstra, Anna Ossowski, Kerstin Becker, Michael Hallek, Bastian von Tresckow, Peter Borchmann, Sven Borchmann

Blood, 2026


Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial


Jan-Michel Heger, Julia Mattlener, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill, Conrad-Amadeus Voltin, Jessica Schneider, Julia K Schleifenbaum, Sophie Heidenreich, Carsten Kobe, Helen Kaul, Wolfram Klapper, Bastian von Tresckow, Peter Borchmann, Paul J Bröckelmann, Sven Borchmann

Blood Adv, 2026


Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma


Marie Anne-Catherine Neumann, Jessica Schneider, Max Szameitat, Philipp Schommers, Sven Borchmann, Michael Hallek, Peter Borchmann, Jan-Michel Heger

Blood Adv, 2026


The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study


Anna Santarsieri, Emily Mitchell, My H Pham, Rashesh Sanghvi, Janina Jablonski, Henry Lee-Six, Katherine Sturgess, Pauline Brice, Tobias F Menne, Wendy Osborne, Thomas Creasey, Kirit M Ardeshna, Joanna Baxter, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D Chavda, Graham P Collins, Dominic J Culligan, Kate Cwynarski, Andrew Davies, Abigail Downing, David Dutton, Michelle Furtado, Eve Gallop-Evans, Andrew Hodson, David Hopkins, Hannah Hsu, Sunil Iyengar, Stephen G Jones, Mamatha Karanth, Kim M Linton, Oliver C Lomas, Nicolas Martinez-Calle, Abhinav Mathur, Pamela McKay, Sateesh K Nagumantry, Elizabeth H Phillips, Neil Phillips, John F Rudge, Nimish K Shah, Gwyneth Stafford, Alex Sternberg, Rachel Trickey, Benjamin J Uttenthal, Natasha Wetherall, Xiao-Yin Zhang, Andrew K McMillan, Nicholas Coleman, Michael R Stratton, Elisa Laurenti, Peter Borchmann, Sven Borchmann, Peter J Campbell, Raheleh Rahbari, George A Follows

Lancet Oncol, 2025


View all

Ongoing projects


Liquid Biopsies


Liquid biopsies allow for easy sampling of a cancer’s genome by a simple blood draw. This not only enables access to crucial molecular information in patients that have difficult-to-biopsy lesions, but it also provides an opportunity to gain insight in...


Translational Research in Hodgkin Lymphoma


In close ties with the German Hodgkin Study Group (GHSG) we archive biomaterials from Hodgkin lymphoma patients within GHSG clinical trials. Building on this large collection of materials we are conducting translational studies to deepen our understand...


Cancer Microbiome


A further axis of our research is the response of the human host to acute and chronic infection and how this response can shape cancer development secondary to infection. We have comprehensively characterized bacterial and viral genomes in over 3000 wh...


Bispecific Antibody Development


Transfer or induction of neo- or tumor-associated antigen specific T-cells can be a core element of successful immunotherapy. However, clinical translation of adoptive cell therapy is technically difficult, expensive, and associated with high regulator...

Contact


AG Borchmann

[email protected]


Department I for Internal Medicine

University Hospital of Cologne

Mailing address:

AG Borchmann
TRIO (Gebäude 66)
Robert-Koch-Straße 21
50931 Cologne
Germany


Share

Translate to